Article · 2015
Conference abstractPublished 19 Aug 2019
Biomarkers in brain-derived exosomes assist the diagnosis of neurodegenerative diseases
University of California, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Biomarkers for neurodegenerative diseases are urgently needed. Definite diagnosis for most diseases is possible only postmortem and the rates of misdiagnosis are high. Monitoring progression and treatment effects using clinical criteria is inefficient due to high variability. Current biomarker strategies, such as brain imaging and cerebrospinal fluid analysis have major drawbacks. An attractive alternative is analysis of biomarkers in brain-derived exosomes isolated from the blood. Methodology & Theoretical Orientation: We examined α-synuclein in neuronal and oligodendroglial exosomes as a diagnostic biomarker for distinguishing between Parkinson’s disease (PD) and multiple system atrophy (MSA). α-Synuclein deposition is found as Lewy bodies in PD and glial cytoplasmic inclusions, primarily in oligodendrocytes, in MSA. We compared cohorts of healthy control individuals, patients with PD, and patients with MSA. Findings: α- Synuclein concentration in both exosome populations were significantly higher in the two diseases than in the controls and in MSA relative to PD. The total α-synuclein levels separated MSA from control with high sensitivity and specificity, whereas the PD group separated only moderately from the other groups. However, the ratio between the α- synuclein levels in the oligodendroglial relative to the neuronal exosomes separated the two disease groups with high sensitivity and specificity. The ratio also correlated significantly with progression of motor symptoms in the PD group. Conclusion & Significance: Measurement of α-synuclein in brain-derived exosomes offers a minimally invasive means for analyzing biomarkers for PD and MSA, suggesting that in the relatively near future these two diseases could for the first time be diagnosed with high sensitivity and specificity, and their progression could be monitored, using a simple blood test.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 12 Sep 2011
Brain-derived neurotrophic factor as a biomarker of acute episodes in bipolar disorder: meta-regression analysis
Research article · 10 May 2017
Association of Brain-Derived Neurotrophic Factor (BDNF) Gene Snps G196A and C270T with Alzheimer's Disease: A Meta-Analysis
Commentary · 28 Oct 2024
The Role of Exosome-Based Biomarkers in Chronic Inflammatory Disease Diagnosis
Short communication · 27 Sep 2022
Approaches to identifying clinically relevant biomarkers for neurodegenerative disease.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNeuroscience & Neurology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Gal Bitan”
